Companies › Grifols Biologicals
2 active drug programs in 2 registered trials: 1 Phase 3, 1 Phase 4; Oncology, Hematology; next expected readout Aug 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Alphanate SD/HT Factor VIII/von Willebrand Factor (vWF) concentrate | F8, VWF | Phase 4 | Von Willebrand Disease | – |
| Gamunex-C, 10% Injectable Solution Intravenous immunoglobulin (IVIG) | – | Phase 3 | Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma | Aug 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT00555555 | Alphanate SD/HT | Phase 4 | Von Willebrand Disease | Hematology | Feb 2012 |
| NCT07582432 | Gamunex-C, 10% Injectable Solution | Phase 3 | Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma | Oncology | Aug 2028 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.